Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.

Alumis Announces Pricing of Initial Public Offering Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering